Brenig Therapeutics to Present AI Designed NLRP3 Inhibitor at Keystone Symposia
Brenig Therapeutics will present new data on its AI designed brain-penetrant NLRP3 inhibitor BT-409 at the Keystone Symposia on Neuroinflammation in Health and Disease, showcasing how its Hybrid AI Platform supports CNS drug discovery.